human papillomavirus News
-
Does volume matter? Impact of collection volumes on detection of biomarkers and HPV DNA in first-void urine
The study by Laura Téblick (University of Antwerp, Belgium) investigated whether varying first-void urine collection volumes, including 4, 10 and 20 mL collected with Colli-Pee, affects the detection of human and viral endpoints (i.e., glyceraldehyde 3-phosphate dehydrogenase (GAPDH), β-actin (ACTB), β-globin (HBB) and Human Papillomavirus (HPV). The results showed that all ...
By Novosanis NV
-
Imaxio signs an option for a license agreement with the German Cancer Research Center (DKFZ)
Imaxio, a biopharmaceutical company specialized in vaccines, today announces that it has signed an option for a license agreement with the world-renowned German Center for Cancer Research (DKFZ – Deutsches Krebsforschungszentrum), based in Heidelberg. The financial terms of the agreement were not disclosed. The DKFZ is to make an internal evaluation of Imaxio’s IMX313 pro-immunogenic ...
By IMAXIO S.A.
-
Imaxio signs a license agreement with the German Cancer Research Center (DKFZ)
Imaxio, a biotech company specializing in immunology announces today that it has signed a license agreement with the world-renowned German Cancer Research Center (DKFZ – Deutsches Krebsforschungszentrum), based in Heidelberg. The financial terms of the agreement were not disclosed. It follows a 2-year evaluation of Imaxio’s IMX313P pro-immunogenic technology by DKFZ under a license ...
By IMAXIO S.A.
-
Royal Government of Bhutan, Merck and Australian Cervical Cancer Foundation partner on vaccination program with GARDASIL(R) for girls and young women of Bhutan
The Royal Government of Bhutan, Merck (which is known as MSD outside the United States and Canada) and the Australian Cervical Cancer Foundation (ACCF) today launched a national vaccination program with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls and young women in Bhutan. In an effort to reduce the burden of cervical cancer, ...
-
Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through Phase 2 Results
Vaccitech Ltd (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announces that it has raised $168 million in a Series B financing. This includes $43 million in convertible loan notes previously issued by Vaccitech that ...
-
HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO
Phase 1 data show single-vector HB-201 and 2-vector HB-202/HB-201 were generally well tolerated, rapidly induced tumor-specific T cells and showed anti-tumor activity in heavily pre-treated head and neck cancer patients Poster presentation to include data supporting recommended Phase 2 dose for alternating 2-vector HB-202/HB-201 and Phase 2 development plans in head and neck cancers HOOKIPA ...
-
Amerigo Scientific Launches Anex® Brush for Optimal Sampling
Amerigo Scientific, a distributor focused on providing critical products and services to the biomedical and life science communities, recently announced the release of a new Anex® Brush that allowed optimal sampling the entire anal canal including the anal transformation zone, without the need for a proctoscope or anoscope. Amerigo Scientific provides high-quality and cost-effective medical ...
-
HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO
Alternating 2-vector therapy showed superior antigen-specific T cell responses, more robust anti-tumor activity and similar tolerability vs. single-vector therapy Phase 2 to proceed with alternating 2-vector therapy in combination with pembrolizumab, which will help inform the randomized Phase 2 trial with pembrolizumab planned to start in the first half of 2023 Additional Phase 2 cohort will ...
-
SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors
WATERTOWN, Mass.--(BUSINESS WIRE)-- SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the company’s lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of HPV16+ advanced or metastatic solid tumors. Fast ...
-
QIAGEN HPV DNA test donation to expand access to cervical cancer screening for women in rural India
QIAGEN today announced a key allocation from the company"s "one million test" donation program to increase access to HPV screening for cervical cancer prevention among women in low-resource regions of the world. Approximately 26,000 human papillomavirus (HPV) tests will go to the Nargis Dutt Memorial Cancer Hospital for cervical cancer screening, the company said at the Women Deliver global ...
-
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany to Evaluate Ficlatuzumab and ERBITUX® (cetuximab) in Patients with Recurrent or Metastatic HNSCC
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany to evaluate ficlatuzumab in combination with ERBITUX® (cetuximab), an EGFR-targeted antibody, in patients with recurrent or metastatic head and neck squamous cell carcinoma ...
-
INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO`s VGX-3100 for advanced cervical dysplasia
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO's therapies. (*Complementary when referring to the US regulatory pathway.) The ...
-
Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that the Company will present a Trials in Progress poster presentation for its lead artificial antigen-presenting (aAPC) cell program, RTX-321, at the American ...
-
Dosing completed
All volunteers have now received three doses of 2AP01 (AAVLP-HPV), our very broad spectrum HPV vaccine formulated without adjuvant. The vaccine is well tolerated and no serious adverse events (SAEs)have been observed to ...
-
New data show HOOKIPA’s arenaviral immunotherapies induce potent T cell responses in novel combinations and against tumor self-antigens
Preclinical data on combination with co-stimulatory 4-1BB agonists or adoptive T cell transfer showed potent T cell responses and significant tumor control Preclinical data also expand evidence on arenaviral immunotherapy targeting tumor self-antigens, reinforcing scientific approach for HB-300 program in prostate cancer Poster presentations at AACR underscore the versatility of ...
-
NeuMoDx HPV Test Strip Assay complies with International Guidelines for HPV screening
This year ECCMID 2021 conference is still fully virtual, nevertheless the data presented are real! Self-screen is proud to announce that the QIAGEN NeuMoDx HPV Test Strip Assay fulfills the International Guidelines for HPV Testing, the so-called Meijer criteria. The data are presented during the QIAGEN symposium on July 12th by dr. Anja Šterbenc MD, PhD from Prof. dr. Mario Poljak’s ...
-
Clinical trials explained
On November 4, Jeanette Prangsgaard held a presentation at the ‘Clinical Trials’ even, organised by Synapse – Life Science Connect Aalborg. Jeanette spoke about clinical trials, what they entail, and what her role is in the process of the development of our prophylactic HPV vaccine, to pique the interest of students and recent graduates. The aim of the event is to bridge the ...
-
QIAsure Methylation Test can decrease clinically non relevant colposcopy referrals of hpv positive women with asc-us/ lsil cytology
British Journal of Cancer; https://doi.org/10.1038/s41416-021-01614-4 Primary HPV screening has doubled the number of colposcopy referrals because of direct referral of HPV-positive women with ASC-US/ LSIL cytology. This study evaluated the CIN3+ risks and colposcopy referrals by QIAsure Methylation Test analysis HPV16/18 genotyping HPV16/18/31/33/45 genotyping in HPV-positive women ...
-
ViciniVax announces first patient treated in Phase I study with immunotherapy Vvax001 for HPV-related precancers and cancer
ViciniVax is pleased to report today that the last patient has completed treatment in the Phase I study with Vvax001. This study was designed to assess the safety and HPV16 E6,7-specific T-cell immune responses upon injection of 4 different doses of Vvax001 in a total of 12 subjects. Full analysis of the data is expected in Q2 2018. ...
By ViciniVax BV
-
Eurogin QIAGEN symposium
During the QIAGEN symposium at Eurogin the latest clinical performance and study data around Self-screen’s molecular screening and triage solutions were presented by excellent scientists. Topic 31 May 2021: Full molecular screening and triage solutions, chaired by Prof. dr. Chris Meijer Presenters: Dr. Bart Hesselink (Self-screen B.V., Netherlands) – Clinical performance of ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you